Strategic Partners

Mosaic is focused on partnerships that combine Mosaic’s proprietary technology and expertise with its partner’s active agents agents or technologies.

Announced partnerships include:

In collaboration with Novartis, we are combining Mosaic’s tissue scaffolding technology with Novartis’s active agents to develop novel products for wound healing.

In collaboration with Catalyst, we are developing intravitreal Anti-Complement Factor 3 (C3) products for the treatment of dry AMD and other retinal diseases.